Charting the path to expanded access for CFTR modulator drugs: the nose knows

被引：3
|
作者：
Bear, Christine [1 ,2 ]
Ratjen, Felix [2 ,3 ,4 ]
机构：
[1] Hosp Sick Children, Res Inst, Mol Med, Toronto, ON, Canada
[2] Univ Toronto, Dept Physiol, Toronto, ON, Canada
[3] Hosp Sick Children, Res Inst, Translat Med, Toronto, ON, Canada
[4] Hosp Sick Children, Dept Pediat, Div Resp Med, Toronto, ON, Canada
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷 / 04期
关键词：
CYSTIC-FIBROSIS; ORGANOIDS;
D O I：
10.1183/13993003.01387-2023
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try
    Manley, Haley
    Sisk, Bryan A.
    Master, Zubin
    Scott, Christopher Thomas
    JOURNAL OF LAW AND THE BIOSCIENCES, 2022, 9 (02):
  • [32] Institutional Review Boards as Arbiters of Expanded Access to Unapproved Drugs: Time for a Change?
    Barbara K. Redman
    Alison Shea Bateman-House
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 515 - 516
  • [33] Estimating the lives that could be saved by expanded access to weight- loss drugs
    Pandey, Abhishek
    Ye, Yang
    Wells, Chad R.
    Singer, Burton H.
    Galvani, Alison P.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (43)
  • [34] Institutional Review Boards as Arbiters of Expanded Access to Unapproved Drugs: Time for a Change?
    Redman, Barbara K.
    Bateman-House, Alison Shea
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (04) : 515 - 516
  • [35] Rapid Drug Desensitization Protocol in Delayed Hypersensitivity Reactions to CFTR Modulator Drugs: When Every Day Counts
    Rodriguez-Otero, N.
    Fernandez-Lozano, C.
    Vicente-Santamaria, S.
    Diaz-Montalvo, L.
    Menendez-Conde, C. Perez
    Sola-Martinez, F. J.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2024, 34 (05)
  • [36] Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor
    Hughes, David L.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (11) : 2302 - 2322
  • [37] Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
    Bacalhau, Mafalda
    Camargo, Mariana
    Magalhaes-Ghiotto, Grace A. V.
    Drumond, Sybelle
    Castelletti, Carlos Henrique M.
    Lopes-Pacheco, Miqueias
    PHARMACEUTICALS, 2023, 16 (03)
  • [38] Study on the Access Path for Patented Drugs to the Basic National Medical Insurance Catalogue
    Chen, Ye
    Liu, Xinyue
    Ding, Xiaomi
    Ding, Jinxi
    Chinese Journal of Pharmaceuticals, 2023, 54 (11) : 1663 - 1670
  • [39] The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications
    Eline M. Bunnik
    Nikkie Aarts
    Suzanne van de Vathorst
    Journal of Pharmaceutical Policy and Practice, 10 (1)
  • [40] Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis
    Vermeulen, Stefan F.
    Hordijk, Marjolijn
    Visser, Ruben J.
    Bunnik, Eline M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2023, 51 (01): : 172 - 180
12345